ID SK-MEL-1 AC CVCL_0068 SY SK-Mel-1; SK Mel 1; SK-Mel 1; SK-Mel1; SKMEL-1; SkMEL-1; SKMEL1; SK 1 DR BTO; BTO_0002129 DR CLO; CLO_0009040 DR CLO; CLO_0037292 DR EFO; EFO_0002332 DR AddexBio; C0020006/4979 DR ArrayExpress; E-MTAB-38 DR ArrayExpress; E-MTAB-2706 DR ArrayExpress; E-MTAB-2770 DR ArrayExpress; E-MTAB-3610 DR ATCC; HTB-67 DR BioSample; SAMN01821599 DR BioSample; SAMN01821665 DR BioSample; SAMN03473224 DR BioSample; SAMN10987654 DR cancercelllines; CVCL_0068 DR CancerTools; 161914 DR CCRID; 1101HUM-PUMC000052 DR Cell_Model_Passport; SIDM01107 DR ChEMBL-Cells; CHEMBL3308365 DR ChEMBL-Targets; CHEMBL614916 DR CLS; 300424 DR Cosmic; 688052 DR Cosmic; 888065 DR Cosmic; 909723 DR Cosmic; 928696 DR Cosmic; 1022279 DR Cosmic; 1303052 DR Cosmic; 1459639 DR Cosmic; 1669128 DR Cosmic; 1995632 DR Cosmic-CLP; 909723 DR DepMap; ACH-000465 DR DSMZ; ACC-303 DR DSMZCellDive; ACC-303 DR EGA; EGAS00001000610 DR EGA; EGAS00001000978 DR EGA; EGAS00001002554 DR GDSC; 909723 DR GEO; GSM784507 DR GEO; GSM827506 DR GEO; GSM887582 DR GEO; GSM888665 DR GEO; GSM1670436 DR IARC_TP53; 27578 DR IGRhCellID; SKMEL1 DR KCB; KCB 200724YJ DR KCLB; 30067 DR LiGeA; CCLE_788 DR LINCS_LDP; LCL-1265 DR PharmacoDB; SKMEL1_1393_2019 DR PRIDE; PXD022992 DR PRIDE; PXD030304 DR Progenetix; CVCL_0068 DR PubChem_Cell_line; CVCL_0068 DR Wikidata; Q54953753 RX PubMed=327080; RX PubMed=833871; RX PubMed=3335022; RX PubMed=3518877; RX PubMed=4879578; RX PubMed=6220172; RX PubMed=6895502; RX PubMed=8755562; RX PubMed=11668190; RX PubMed=20164919; RX PubMed=20215515; RX PubMed=21725359; RX PubMed=22460905; RX PubMed=24576830; RX PubMed=25485619; RX PubMed=25877200; RX PubMed=26589293; RX PubMed=27397505; RX PubMed=28196595; RX PubMed=30629668; RX PubMed=30894373; RX PubMed=31068700; RX PubMed=35839778; WW Info; MCLP; -; https://tcpaportal.org/mclp/ WW Provider; MSKCC; -; https://www.mskcc.org/research-advantage/support/technology/tangible-material/human-melanoma-cell-line-sk-mel-1 CC Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). CC Part of: COSMIC cell lines project. CC Part of: MD Anderson Cell Lines Project. CC From: Memorial Sloan Kettering Cancer Center; New York; USA. CC Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2004-052. CC Population: Caucasian. CC Doubling time: ~100 hours (DSMZ=ACC-303). CC HLA typing: A*26:01,26:01; B*38:01,67:02; C*04:01,12:03; DQA1*03:02,03:02; DQB1*06:01,06:01; DRB1*14:76,14:76 (PubMed=26589293). CC Microsatellite instability: Stable (MSS) (Sanger). CC Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21725359; PubMed=24576830; Cosmic-CLP=909723; DepMap=ACH-000465). CC Sequence variation: Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Ser33Cys (c.98C>G); ClinVar=VCV000376231; Zygosity=Heterozygous (ATCC=HTB-67; Cosmic-CLP=909723; DepMap=ACH-000465). CC Omics: Genomics; DNA methylation analysis. CC Omics: Genomics; Whole exome sequencing. CC Omics: Phenotyping; Drug screening. CC Omics: Proteomics. CC Omics: Proteomics; Expression; Reverse-phase protein array. CC Omics: Proteomics; PTM; Phosphorylation. CC Omics: Proteomics; Quantitative. CC Omics: Transcriptomics; Microarray. CC Omics: Transcriptomics; RNAseq. CC Omics: Variations; SNP array analysis. CC Genome ancestry: African=1.29%; Native American=0%; East Asian, North=4.27%; East Asian, South=0%; South Asian=9.23%; European, North=23.14%; European, South=62.08% (PubMed=30894373). CC Derived from site: Metastatic; Thoracic lymph duct; UBERON=UBERON_0007644. ST Source(s): AddexBio=C0020006/4979; ATCC=HTB-67; CCRID=1101HUM-PUMC000052; CLS=300424; Cosmic-CLP=909723; DSMZ=ACC-303; KCLB=30067; PubMed=25877200 ST Amelogenin: X,Y ST CSF1PO: 12,13 ST D13S317: 11 ST D16S539: 11,12 ST D18S51: 13,16 ST D19S433: 15 (DSMZ=ACC-303) ST D19S433: 15,16.2 (ATCC=HTB-67; CCRID=1101HUM-PUMC000052) ST D21S11: 29,32.2 ST D2S1338: 19,23 ST D3S1358: 14,16 ST D5S818: 12,13 ST D7S820: 12 ST D8S1179: 13,16 (ATCC=HTB-67; CLS=300424; DSMZ=ACC-303; PubMed=25877200) ST D8S1179: 16 (CCRID=1101HUM-PUMC000052) ST FGA: 17,20 (DSMZ=ACC-303) ST FGA: 18,20 (ATCC=HTB-67; CCRID=1101HUM-PUMC000052; CLS=300424; PubMed=25877200) ST Penta D: 11,13 ST Penta E: 7,21 ST TH01: 6 ST TPOX: 11 ST vWA: 16,17 DI NCIt; C3224; Melanoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) SX Male AG 29Y CA Cancer cell line DT Created: 04-04-12; Last updated: 10-04-25; Version: 45 // RX PubMed=327080; DOI=10.1093/jnci/59.1.221; RA Fogh J., Fogh J.M., Orfeo T.; RT "One hundred and twenty-seven cultured human tumor cell lines RT producing tumors in nude mice."; RL J. Natl. Cancer Inst. 59:221-226(1977). // RX PubMed=833871; DOI=10.1093/jnci/58.2.209; RA Fogh J., Wright W.C., Loveless J.D.; RT "Absence of HeLa cell contamination in 169 cell lines derived from RT human tumors."; RL J. Natl. Cancer Inst. 58:209-214(1977). // RX PubMed=3335022; RA Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., RA Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.; RT "Feasibility of drug screening with panels of human tumor cell lines RT using a microculture tetrazolium assay."; RL Cancer Res. 48:589-601(1988). // RX PubMed=3518877; DOI=10.3109/07357908609038260; RA Fogh J.; RT "Human tumor lines for cancer research."; RL Cancer Invest. 4:157-184(1986). // RX PubMed=4879578; DOI=10.1093/jnci/41.4.827; RA Oettgen H.F., Aoki T., Old L.J., Boyse E.A., de Harven E., Mills G.M.; RT "Suspension culture of a pigment-producing cell line derived from a RT human malignant melanoma."; RL J. Natl. Cancer Inst. 41:827-843(1968). // RX PubMed=6220172; RA Dracopoli N.C., Fogh J.; RT "Polymorphic enzyme analysis of cultured human tumor cell lines."; RL J. Natl. Cancer Inst. 70:469-476(1983). // RX PubMed=6895502; DOI=10.1002/eji.1830111015; RA Johnson J.P., Demmer-Dieckmann M., Meo T., Hadam M.R., Riethmuller G.; RT "Surface antigens of human melanoma cells defined by monoclonal RT antibodies. I. Biochemical characterization of two antigens found on RT cell lines and fresh tumors of diverse tissue origin."; RL Eur. J. Immunol. 11:825-831(1981). // RX PubMed=8755562; DOI=10.1073/pnas.93.15.7832; PMCID=PMC38834; RA Liu D.-C., Pearlman E., Diaconu E., Guo K., Mori H., Haqqi T., RA Markowitz S.D., Willson J.K.V., Sy M.-S.; RT "Expression of hyaluronidase by tumor cells induces angiogenesis in RT vivo."; RL Proc. Natl. Acad. Sci. U.S.A. 93:7832-7837(1996). // RX PubMed=11668190; DOI=10.1177/002215540104901105; RA Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.; RT "Immunocytochemical analysis of cell lines derived from solid RT tumors."; RL J. Histochem. Cytochem. 49:1369-1378(2001). // RX PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113; RA Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., RA Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., RA Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., RA Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.; RT "Signatures of mutation and selection in the cancer genome."; RL Nature 463:893-898(2010). // RX PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662; RA Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., RA Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., RA Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., RA Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., RA Haber D.A.; RT "A genome-wide screen for microdeletions reveals disruption of RT polarity complex genes in diverse human cancers."; RL Cancer Res. 70:2158-2164(2010). // RX PubMed=21725359; DOI=10.1038/onc.2011.250; PMCID=PMC3267014; RA Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M., RA She Q.-B., Gallardo H.F., Liu C., Merghoub T., Hefter B.E., Dolgalev I., RA Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G., RA Wolchok J.D., Houghton A.N., Solit D.B.; RT "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF RT dependence in melanomas harboring (V600E)BRAF."; RL Oncogene 31:446-457(2012). // RX PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027; RA Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., RA Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., RA Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., RA Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., RA Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., RA Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., RA Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., RA Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., RA Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., RA Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., RA Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.; RT "The Cancer Cell Line Encyclopedia enables predictive modelling of RT anticancer drug sensitivity."; RL Nature 483:603-607(2012). // RX PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625; PMCID=PMC4005042; RA Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L., RA Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A., RA Chapman P.B., Yaeger R.D., Taylor B.S., Schultz N., Berger M.F., RA Rosen N., Solit D.B.; RT "Loss of NF1 in cutaneous melanoma is associated with RAS activation RT and MEK dependence."; RL Cancer Res. 74:2340-2350(2014). // RX PubMed=25485619; DOI=10.1038/nbt.3080; RA Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., RA Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., RA Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., RA Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., RA Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., RA Settleman J., Seshagiri S., Zhang Z.-M.; RT "A comprehensive transcriptional portrait of human cancer cell RT lines."; RL Nat. Biotechnol. 33:306-312(2015). // RX PubMed=25877200; DOI=10.1038/nature14397; RA Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., RA Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., RA Neve R.M.; RT "A resource for cell line authentication, annotation and quality RT control."; RL Nature 520:307-311(2015). // RX PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878; RA Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., RA Loewer M., Sahin U., Castle J.C.; RT "TCLP: an online cancer cell line catalogue integrating HLA type, RT predicted neo-epitopes, virus and gene expression."; RL Genome Med. 7:118.1-118.7(2015). // RX PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469; RA Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., RA Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., RA Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., RA Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., RA Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., RA Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., RA Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., RA Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.; RT "A landscape of pharmacogenomic interactions in cancer."; RL Cell 166:740-754(2016). // RX PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076; RA Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., RA Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., RA Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., RA Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., RA Liang H.; RT "Characterization of human cancer cell lines by reverse-phase protein RT arrays."; RL Cancer Cell 31:225-239(2017). // RX PubMed=30629668; DOI=10.1371/journal.pone.0210404; PMCID=PMC6328144; RA Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.; RT "Screening human cell lines for viral infections applying RNA-Seq data RT analysis."; RL PLoS ONE 14:e0210404.1-e0210404.22(2019). // RX PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675; RA Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.; RT "An interactive resource to probe genetic diversity and estimated RT ancestry in cancer cell lines."; RL Cancer Res. 79:1263-1273(2019). // RX PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103; RA Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., RA McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., RA Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., RA Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., RA Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., RA Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., RA Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., RA Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., RA Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., RA Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., RA Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., RA Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., RA Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., RA Sellers W.R.; RT "Next-generation characterization of the Cancer Cell Line RT Encyclopedia."; RL Nature 569:503-508(2019). // RX PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775; RA Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., RA Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., RA Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., RA Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., RA Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., RA Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.; RT "Pan-cancer proteomic map of 949 human cell lines."; RL Cancer Cell 40:835-849.e8(2022). //